News

HDA UK Media And Political Bulletin – 16 October 2017

Media and Political Bulletin

16 October 2017

Media Summary

Drug Companies Fear Brexit Will Hit Medicine Trade

Bloomberg, John Lauerman, 16 October 2017

 

Bloomberg highlights that time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

 

Alan Morrison, vice president of regulatory affairs international for Merck & Co., said in an interview in London last week that  a myriad of issues, including guidance on transferring product registration and drug testing in the region, are yet to be resolved. The problem is particularly acute for drug and biotech companies whose products sometimes take years to make, test and navigate through regulatory channels.

 

Concerns about a messy breakup are flaring after chief EU negotiator Michel Barnier said last week that discussions with the U.K. are “in a state of deadlock.”

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

Drug Companies Fear Brexit Will Hit Medicine Trade

Bloomberg, John Lauerman, 16 October 2017

 

Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

 

A myriad of issues, including guidance on transferring product registration and drug testing in the region, are yet to be resolved, Alan Morrison, vice president of regulatory affairs international for Merck & Co., said in an interview in London. The problem is particularly acute for drug and biotech companies whose products sometimes take years to make, test and navigate through regulatory channels.

 

“Will we be able to do everything on time? Probably not,” Morrison said.

 

Concerns about a messy breakup are flaring after chief EU negotiator Michel Barnier said last week that discussions with the U.K. are “in a state of deadlock.” AstraZeneca Plc Chief Executive Officer Pascal Soriot warned last month that it was “impossible” for the government to forge new trade accords, establish a regulatory framework and develop new procedures for shipping products by the time the country exits the EU in 2019. Others echoed that sentiment, saying questions hang over a host of issues from duties and tariffs to the movement of products and people over borders.

 

“There could be some administrative delays to products being available in Europe,” Morrison said. Just changing registrations for medicines — which have to be filed in a EU member state to be recognized through the region — will be “a large logistical exercise in every company having to make the appropriate market transfer.”

 

Stale Lists

 

While Brexit leaders have suggested that the U.K. could revert to World Trade Organization rules, drugmakers counter that the WTO list of pharmaceuticals is far out of date. Products that aren’t on the list might be subject to tariffs for further restriction.

 

“The list hasn’t been updated since 2010,” David Boyd, Cambridge, England-based AstraZeneca’s director of European government affairs, said in an interview. Any drugs that the U.K.’s second-largest drugmaker has introduced over the past seven years wouldn’t be included, he said.

 

Pharma and biotech companies that depend on access to highly skilled employees are also concerned about Brexit’s impact. And those companies aren’t alone.

 

The top European drugs regulator, set to relocate from London following Brexit, could lose more than seven out of 10 employees, a survey of its staff showed. The exodus would trigger a “public health crisis,” the European Medicines Agency said last month.

 

Potential hires are increasingly concerned about their status following the U.K.’s move, Boyd said.

 

“There’s a lot of anxiety,” he said Friday in London.

HDA UK Media And Political Bulletin – 16 October 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?